WallStreetZenWallStreetZen

NASDAQ: DCPH
Deciphera Pharmaceuticals Inc Stock

$14.23-0.49 (-3.33%)
Updated Apr 18, 2024
DCPH Price
$14.23
Fair Value Price
N/A
Market Cap
$1.15B
52 Week Low
$9.90
52 Week High
$17.73
P/E
-6.21x
P/B
3.28x
P/S
8.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$163.36M
Earnings
-$194.94M
Gross Margin
97.7%
Operating Margin
-119.07%
Profit Margin
-119.3%
Debt to Equity
0.35
Operating Cash Flow
-$147M
Beta
1.2
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

DCPH Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DCPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DCPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DCPH is poor value based on its book value relative to its share price (3.28x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.04x)
P/B vs Industry Valuation
DCPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DCPH due diligence checks available for Premium users.

Be the first to know about important DCPH news, forecast changes, insider trades & much more!

DCPH News

Valuation

DCPH fair value

Fair Value of DCPH stock based on Discounted Cash Flow (DCF)
Price
$14.23
Fair Value
$15.52
Undervalued by
8.29%
DCPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DCPH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.21x
Industry
46.58x
Market
41.33x

DCPH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.28x
Industry
2.04x
DCPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DCPH's financial health

Profit margin

Revenue
$48.3M
Net Income
-$47.2M
Profit Margin
-97.7%
DCPH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DCPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$473.6M
Liabilities
$122.7M
Debt to equity
0.35
DCPH's short-term assets ($381.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DCPH's short-term assets ($381.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DCPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DCPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$28.8M
Investing
$2.2M
Financing
$890.0k
DCPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DCPH vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
DCPH$1.15B-3.33%-6.21x3.28x
COLL$1.11B-1.92%24.31x5.69x
IRWD$1.19B-0.65%-1.18x-3.44x
PCRX$1.21B-2.50%28.68x1.39x
TLRY$1.33B0.00%-3.91x0.40x

Deciphera Pharmaceuticals Stock FAQ

What is Deciphera Pharmaceuticals's quote symbol?

(NASDAQ: DCPH) Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol DCPH. Deciphera Pharmaceuticals stock quotes can also be displayed as NASDAQ: DCPH.

If you're new to stock investing, here's how to buy Deciphera Pharmaceuticals stock.

What is the 52 week high and low for Deciphera Pharmaceuticals (NASDAQ: DCPH)?

(NASDAQ: DCPH) Deciphera Pharmaceuticals's 52-week high was $17.73, and its 52-week low was $9.90. It is currently -19.74% from its 52-week high and 43.74% from its 52-week low.

How much is Deciphera Pharmaceuticals stock worth today?

(NASDAQ: DCPH) Deciphera Pharmaceuticals currently has 80,800,062 outstanding shares. With Deciphera Pharmaceuticals stock trading at $14.23 per share, the total value of Deciphera Pharmaceuticals stock (market capitalization) is $1.15B.

Deciphera Pharmaceuticals stock was originally listed at a price of $17.65 in Sep 28, 2017. If you had invested in Deciphera Pharmaceuticals stock at $17.65, your return over the last 6 years would have been -19.38%, for an annualized return of -3.53% (not including any dividends or dividend reinvestments).

How much is Deciphera Pharmaceuticals's stock price per share?

(NASDAQ: DCPH) Deciphera Pharmaceuticals stock price per share is $14.23 today (as of Apr 18, 2024).

What is Deciphera Pharmaceuticals's Market Cap?

(NASDAQ: DCPH) Deciphera Pharmaceuticals's market cap is $1.15B, as of Apr 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Deciphera Pharmaceuticals's market cap is calculated by multiplying DCPH's current stock price of $14.23 by DCPH's total outstanding shares of 80,800,062.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.